LYRA — Lyra Therapeutics, Inc.

OTC · Health Care · Health Care Equipment & Supplies · CIK 1327273 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 7,000 -6,911,000 -6,951,000 36,108,000 15,893,000 46,825,000
Sep 2025 25,000 -6,258,000 -5,984,000 43,709,000 22,055,000 48,037,000
Jun 2025 183,000 -8,428,000 -7,437,000 52,573,000 29,784,000 50,951,000
Mar 2025 183,000 -7,956,000 -8,547,000 56,316,000 31,735,000 52,444,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-28,859,000
Investing CF
$-98,000
Financing CF
$4,273,000
CapEx
$-147,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-24.46
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-433,709,000
Inventory
Receivables
ST Investments
$0
EBIT TTM
$-29,553,000
Pretax Income TTM
$-28,908,000
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$398,000
EBITDA
$-29,094,000
Free Cash Flow
$-17,529,624
Enterprise Value
$15,697,162
Total Cash
$15,893,000
Total Debt
$30,259,000
Shares Out
1,774,882
Trailing EPS
$-18.62
Book Value
$-6.04
ROE
-6595.0%
ROA
-36.1%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 398,000 -29,553,000 -28,919,000 36,108,000 46,825,000 -28,859,000
Dec 2024 1,534,000 -60,733,000 -93,435,000 66,346,000 54,752,000 -70,011,000
Dec 2023 1,558,000 -65,528,000 -62,680,000 142,600,000 53,180,000 -63,304,000
Dec 2022 1,363,000 -54,990,000 -55,278,000 109,968,000 29,214,000 -43,385,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.99

Peers — same industry

TickerNameMarket CapLastDaily %
ISRG INTUITIVE SURGICAL INC $154.64B $436.64
SYK STRYKER CORP $119.99B $313.00
MDT Medtronic plc $99.63B $77.60
BSX BOSTON SCIENTIFIC CORP $85.67B $57.64
MMM 3M CO $80.34B $154.03

News headlines (Yahoo Finance, 1h cache)

Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
2026-04-17 12:00 · Yahoo
Lyra Therapeutics suspends further development of LYR-210
2026-01-13 12:26 · Yahoo
Top Midday Decliners
2026-01-12 20:18 · Yahoo
Lyra Therapeutics Provides Corporate Update
2026-01-12 12:00 · Yahoo
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-12 21:01 · Yahoo
Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates
2025-11-10 22:45 · Yahoo
Dentsply International (XRAY) Lags Q3 Earnings Estimates
2025-11-06 14:15 · Yahoo
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
2025-11-04 14:15 · Yahoo
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
2025-10-06 11:00 · Yahoo
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
2025-08-12 21:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.